Figure 1. Participant Flow in the PhALLCON Trial.

^aThere were 332 screening assessments of 330 patients; 2 patients were rescreened after not meeting eligibility initially. One patient approached for eligibility screening did not consent.

^bThe 2 patients rescreened as mentioned in footnote a are included in reasons for exclusion but are not counted in the total number of patients excluded (n = 85).

^cThis patient died of COVID-19 after randomization and before receiving any dose of ponatinib.

^dReasons for discontinuation derived from electronic case report forms completed by study site personnel. One patient randomized to imatinib was discontinued due to a fatal adverse event; the reason for discontinuation was not reported.

^eOther reasons included loss of minimum residual disease negativity and investigator decision to start another treatment (n = 1), loss of cytogenic response (n = 1), and patient not agreeing to study procedure and polymerase chain reaction not at an ideal level (n = 1).

^fOther reasons included nonadherence to treatment visits and no longer meeting inclusion criteria (n = 1) and a report of “completed” (additional information not available; n = 1).